H‐J Stellbrink

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

Christian Hoffmann, Tanya Welz, Michael Sabranski et al. · HIV Medicine · 2016 · 281 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Switching to coformulated rilpivirine (<scp>RPV</scp>), emtricitabine (<scp>FTC</scp>) and tenofovir alafenamide from either <scp>RPV</scp>,<scp> FTC</scp> and tenofovir disoproxil fumarate (<scp>TDF</scp>) or efavirenz, <scp>FTC</scp> and <scp>TDF</scp>: 96‐week results from two randomized clinical trials

D Hagins, Chloe Orkin, ES Daar et al. · HIV Medicine · 2018 · 47 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Multiple hepatitis <scp>C</scp> virus (<scp>HCV</scp>) reinfections in <scp>HIV</scp>‐positive men who have sex with men: no influence of <scp>HCV</scp> genotype switch or interleukin‐28<scp>B</scp> genotype on spontaneous clearance

Patrick Ingiliz, Ivanka Krznaric, H‐J Stellbrink et al. · HIV Medicine · 2014 · 39 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

High prevalence of comorbidities and use of concomitant medication in treated people living with HIV in Germany – results of the BESIDE study

Benjamin Funke, CD Spinner, Eva Wolf et al. · International Journal of STD & AIDS · 2020 · 23 citations

Public Health, Health Sciences, Clinical Epidemiology +16